Steven Lichtman
Stock Analyst
(4.76)
# 890
Out of 4,648 analysts
67
Total ratings
66.67%
Success rate
34.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Outperform | $115 → $105 | $70.16 | +49.66% | 8 | Oct 25, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $107.82 | +25.21% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $7.26 | +65.29% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $91.96 | +19.62% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $89.59 | +4.92% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $51.68 | +25.77% | 8 | Aug 6, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $47 → $58 | $32.50 | +78.46% | 1 | Jun 10, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $10.35 | +6.28% | 5 | May 9, 2024 | |
| ANGO AngioDynamics | Upgrades: Outperform | $12 | $6.77 | +77.38% | 2 | Apr 5, 2024 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $82 → $87 | $99.44 | -12.51% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $58 → $68 | $84.00 | -19.05% | 2 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $2.23 | +57.30% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $300 → $275 | $236.59 | +16.23% | 5 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $365.21 | -21.14% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $132.89 | -20.99% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $29.11 | +415.29% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $105.18 | -19.19% | 3 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.79 | - | 2 | Apr 12, 2017 |
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $70.16
Upside: +49.66%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $107.82
Upside: +25.21%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $7.26
Upside: +65.29%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $91.96
Upside: +19.62%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $89.59
Upside: +4.92%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $51.68
Upside: +25.77%
Tandem Diabetes Care
Jun 10, 2024
Maintains: Outperform
Price Target: $47 → $58
Current: $32.50
Upside: +78.46%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $10.35
Upside: +6.28%
AngioDynamics
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $6.77
Upside: +77.38%
Merit Medical Systems
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $99.44
Upside: -12.51%
Feb 1, 2024
Maintains: Perform
Price Target: $58 → $68
Current: $84.00
Upside: -19.05%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $2.23
Upside: +57.30%
Jan 31, 2022
Upgrades: Outperform
Price Target: $300 → $275
Current: $236.59
Upside: +16.23%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $365.21
Upside: -21.14%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $132.89
Upside: -20.99%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $29.11
Upside: +415.29%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $105.18
Upside: -19.19%
Apr 12, 2017
Downgrades: Perform
Price Target: n/a
Current: $0.79
Upside: -